Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
Tags
Data and Resources
To access the resources you must log in
This item has no data
Item URL
http://data.d4science.org/ctlg/RISIS2OpenData/dedup_wf_001--b5590425e1a4c70c0783e2298d3669ba |
|
Identity
Access Modality
Field | Value |
---|---|
Access Right | not available |
Attribution
Field | Value |
---|---|
Author | Garcia-Manero, Guillermo |
Author | Almeida, Antonio |
Author | Aristoteles Giagounidis |
Author | Platzbecker, Uwe |
Author | Garcia, Regina |
Author | Voso, Maria |
Author | Larsen, Stephen |
Author | Valcarcel, David |
Author | Silverman, Lewis |
Author | Skikne, Barry |
Author | Santini, Valeria |
Publishing
Field | Value |
---|---|
Collected From | Datacite |
Hosted By | figshare |
Publication Date | 2016-01-01 |
Publisher | Figshare |
Additional Info
Field | Value |
---|---|
Language | UNKNOWN |
Resource Type | Collection |
keyword | FOS: Mathematics |
keyword | FOS: Health sciences |
keyword | FOS: Biological sciences |
keyword | FOS: Clinical medicine |
system:type | other |
Management Info
Field | Value |
---|---|
Source | https://science-innovation-policy.openaire.eu/search/other?orpId=dedup_wf_001::b5590425e1a4c70c0783e2298d3669ba |
Author | jsonws_user |
Last Updated | 19 December 2020, 20:50 (CET) |
Created | 19 December 2020, 20:50 (CET) |